Adagene

Adagene (NASDAQ: ADAG) is a platform-driven biopharmaceutical company with proprietary platforms producing clinical-stage products. The company is committed to discovering and developing novel cancer immunotherapies based on original antibodies. Leveraging a powerful platform that combines computational biology and artificial intelligence, we have developed new antibodies with high safety and efficacy, bringing hope to more cancer patients. Our antibody discovery engine — the "Dynamic Precision Library" — is driving the development of Adagene’s pipeline, aiming to create potentially globally innovative or best-in-class products. We have established strategic partnerships with several well-known global companies. These partners fully utilize our cutting-edge technologies, such as safer precision-targeted antibody-drug conjugates (ADCs) and innovative antibody designs. Under the leadership of a world-class core team in the field of precision antibody engineering, Adagene is dedicated to providing groundbreaking solutions for long-standing therapeutic challenges.